Skip to main content
    A

    Akebia Ther (AKBA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.45
    -0.03 (-5.40%)

    Market Cap: $131.67M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Akebia Ther (AKBA) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Akebia Ther (AKBA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Akebia Ther reported EPS of -$0.04, below the -$0.03 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    -12.29%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.04
    Range-$0.07 - -$0.01
    8 analysts
    Revenue Consensus
    $32.80M
    Range$26.26M - $37.80M
    8 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.09
    Range-$0.09 - -$0.09
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.06-50.0%
    60d ago-$0.10+5.3%
    30d ago-$0.10+5.3%
    7d ago-$0.10+5.3%
    Current-$0.09
    Revenue Consensus
    $25.07M
    Range$18.60M - $30.50M
    4 analysts

    Next Report

    AKBA has an expected report date of Feb 24, 2027.

    AKBA Earnings Call

    The latest AKBA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, AKBA beat 16, missed 23 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $36.90M, down 37.2% from $58.77M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.04-$0.03-$0.04 - -$0.02-33.33%Miss-2100.0%21 up, 0 downNov 5, 2026$36.90M
    Jun 30, 2026-$0.02-$0.03-$0.03 - -$0.02+33.33%Beat-174.9%21 up, 0 downAug 5, 2026$49.13M
    Mar 31, 2026-$0.03-$0.02-$0.02 - $0.01-50.00%Miss-250.0%20 up, 0 downMay 7, 2026$53.54M
    Dec 31, 2025-$0.05-$0.03N/A-66.67%MissN/A20 up, 1 downFeb 26, 2026$57.62M
    Sep 30, 2025$0.00-$0.04N/A+105.00%BeatN/A1N/ANov 10, 2025$58.77M
    Jun 30, 2025$0.03-$0.02-$0.04 - -$0.01+233.50%BeatN/A20 up, 1 downAug 7, 2025$62.47M
    Mar 31, 2025$0.02-$0.04-$0.04 - -$0.04+150.00%BeatN/A21 up, 1 downMay 8, 2025$57.34M
    Dec 31, 2024-$0.10-$0.08-$0.11 - -$0.04-33.33%Miss-3225.0%20 up, 0 downMar 13, 2025$46.50M
    Sep 30, 2024-$0.10-$0.05-$0.09 - -$0.03-100.00%MissN/A30 up, 0 downNov 7, 2024$37.43M
    Jun 30, 2024-$0.04-$0.05-$0.08 - -$0.03+20.00%BeatN/A30 up, 0 downAug 8, 2024$43.65M
    Mar 31, 2024-$0.08-$0.09-$0.11 - -$0.05+11.11%BeatN/A30 up, 0 downMay 9, 2024$32.61M
    Dec 31, 2023$0.00-$0.04-$0.06 - -$0.03+108.00%BeatN/A30 up, 0 downMar 14, 2024$56.20M
    Sep 30, 2023-$0.08-$0.08-$0.10 - -$0.070.00%In lineN/A20 up, 0 downNov 8, 2023$42.05M
    Jun 30, 2023-$0.06-$0.02-$0.05 - $0.00-200.00%Miss-126.1%20 up, 0 downAug 25, 2023$56.38M
    Mar 31, 2023-$0.14-$0.15-$0.16 - -$0.14+6.67%BeatN/A20 up, 0 downMay 8, 2023$40.01M
    Dec 31, 2022-$0.04-$0.19-$0.27 - -$0.14+78.95%BeatN/A30 up, 0 downMar 9, 2023$117.41M
    Sep 30, 2022-$0.29-$0.12-$0.22 - -$0.12-141.67%MissN/A30 up, 0 downNov 3, 2022$48.71M
    Jun 30, 2022$0.23-$0.33-$0.36 - -$0.26+169.70%BeatN/A40 up, 0 downAug 4, 2022$126.36M
    Mar 31, 2022-$0.35-$0.29-$0.36 - -$0.22-20.69%MissN/A60 up, 0 downMay 9, 2022N/A
    Dec 31, 2021-$0.40-$0.33-$0.44 - -$0.25-21.21%MissN/A7N/AMar 1, 2022$57.68M
    Sep 30, 2021-$0.34-$0.29-$0.42 - -$0.27-17.24%MissN/A61 up, 0 downNov 4, 2021$48.76M
    Jun 30, 2021-$0.51-$0.31-$0.51 - -$0.16-64.52%MissN/A8N/AAug 5, 2021$52.91M
    Mar 31, 2021-$0.45-$0.36-$0.55 - $0.17-25.00%MissN/A8N/AMay 10, 2021$52.30M
    Dec 31, 2020-$0.60-$0.40-$0.51 - -$0.29-50.00%MissN/A7N/AFeb 25, 2021$56.04M
    Sep 30, 2020-$0.42-$0.24-$0.33 - $0.20-75.00%MissN/A8N/ANov 5, 2020$59.99M
    Jun 30, 2020-$0.44-$0.47-$0.74 - -$0.32+6.38%BeatN/A8N/AAug 10, 2020$90.14M
    Mar 31, 2020-$0.47-$0.60-$0.74 - -$0.48+21.67%BeatN/A8N/AMay 5, 2020$88.48M
    Dec 31, 2019-$0.79-$0.47-$0.55 - -$0.26-68.09%MissN/A8N/AMar 10, 2020$69.56M
    Sep 30, 2019-$0.46-$0.41-$0.52 - -$0.31-12.20%MissN/A7N/ANov 12, 2019$91.98M
    Jun 30, 2019-$0.49-$0.35-$0.45 - -$0.14-40.00%MissN/A7N/AAug 8, 2019$100.80M
    Mar 31, 2019-$0.62-$0.40-$0.52 - -$0.25-55.00%MissN/A8N/AMay 9, 2019$72.67M
    Dec 31, 2018-$0.93-$0.38-$0.53 - $0.43-144.74%Miss-472.0%6N/AMar 26, 2019$59.85M
    Sep 30, 2018-$0.46-$0.56-$1.13 - -$0.47+17.86%BeatN/A7N/ANov 8, 2018$53.17M
    Jun 30, 2018-$0.60-$0.42-$0.83 - -$0.33-42.86%MissN/A7N/AAug 8, 2018$48.79M
    Mar 31, 2018-$0.48-$0.53-$0.99 - -$0.37+9.43%BeatN/A8N/AMay 9, 2018$45.93M
    Dec 31, 2017$0.25-$0.35-$0.59 - $0.00+171.43%BeatN/A9N/AMar 12, 2018$90.56M
    Sep 30, 2017-$0.49-$0.46-$0.79 - -$0.24-6.52%MissN/A7N/ANov 8, 2017$41.28M
    Jun 30, 2017-$0.53-$0.92-$1.24 - -$0.76+42.39%BeatN/A5N/AAug 8, 2017$28.52M
    Mar 31, 2017-$1.15-$0.41N/A-180.49%MissN/AN/AN/AMay 9, 2017$20.86M
    Dec 31, 2016-$0.99$0.77N/A-228.57%MissN/AN/AN/AMar 6, 2017$1.53M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.00, after -$0.32 the year before. It was -$3.60 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.00N/A
    Dec 31, 2024-$0.32N/A
    Dec 31, 2023-$0.28N/A
    Dec 31, 2022-$0.45N/A
    Dec 31, 2021-$1.70N/A
    Dec 31, 2020-$1.93N/A
    Dec 31, 2019-$2.36N/A
    Dec 31, 2018-$2.47N/A
    Dec 31, 2017-$1.92N/A
    Dec 31, 2016-$3.60N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,31212
    2026Q1Mar 31, 20264,07810
    2025Q4Dec 31, 20255,1138
    2025Q3Sep 30, 20255,2479
    2025Q2Jun 30, 20254,5898
    2025Q1Mar 31, 20255,94610
    2024Q4Dec 31, 20245,5238
    2024Q3Sep 30, 20245,3418

    2026Q3 Earnings Call

    Opening remarks

    Mercedes Carrasco Senior Director, Investor Relations Thank you, and welcome to Akebia's third quarter 2026 financial results and business updates conference call. Please note that a press release was issued earlier today, Thursday, November 5th, detailing our third quarter 2026 financial results, and that release is available on the investor section of our website. For your convenience, a replay of today's call will also be available on our website after we conclude. Joining me for today's call, we have John Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer. Dr. Steven Burke, our Chief Medical Officer, and Nicholas Grund, Chief Commercial Officer, are also available for questions. I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on November 5th, as well as in the risks, factors, and management discussion and analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce our CEO, John Butler.

    John Butler CEO Thanks, Mercedes. Good morning, everyone, and thank you for joining us today. Late last month, Akebia joined our peers at ASN Kidney Week in Denver. I left the event with two important takeaways. First, I heard tremendous excitement about the VOICE trial data that Dr. Block of USRC presented. We believe the data, which demonstrated a clear and compelling hospitalization outcomes benefit for vadadustat versus an ESA, dosed in a regimen that most dialysis providers have chosen to implement, will have dialysis organizations thinking differently about Vafseo, and over time has the potential to drive Vafseo to become standard of care. Second, the spotlight continues to shine on rare kidney disease therapeutic product development, and we're excited about the potential to show meaningful differentiation with our mid-stage pipeline assets across multiple rare kidney indications. We believe this would represent significant value for our shareholders. Now, with this backdrop, let me walk through Q3, starting with our commercial business. We are pleased with the pace at which we are adding patients from the mid-sized dialysis providers, including USRC, DCI, and IRC. Last quarter, the number of patients on Vafseo increased to about 11,500 patients on therapy, representing about 20% of patients treated for anemia within these three dialysis organizations. Also important, 25% of patients that had previously discontinued therapy have restarted. Even with this progress, I believe we have significant room to continue driving growth even within the mid-sized dialysis providers, but obviously and especially at the large dialysis organizations.

    Frequently Asked Questions About AKBA

    When is Akebia Ther's next earnings date?

    Akebia Ther's next earnings report is expected for Feb 24, 2027.

    Did AKBA beat earnings estimates last quarter?

    No. Akebia Ther reported EPS of -$0.04 for the quarter ended Sep 30, 2026, below the -$0.03 estimate by 33.33%.

    What EPS do analysts expect from AKBA next quarter?

    The consensus EPS estimate for Akebia Ther for the quarter ending Dec 31, 2026 is -$0.04 from 8 analysts, with estimates from -$0.07 to -$0.01.

    How often does AKBA beat earnings estimates?

    Akebia Ther beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +42.31%.